The Chemours Company is a Wilmington, Delaware-based global chemistry company with leading market positions in Thermal & Specialized Solutions (TSS), Titanium Technologies (TT), and Advanced Performance Materials (APM), and the company is in the middle of a fiscal second quarter that demonstrates the kind of deleveraging-and-pricing pivot the specialty chemicals cohort has been waiting for. Q2 2026 net sales of $1,591 million were approximately flat compared to the prior-year quarter's $1,615 million, the Q2 2026 net loss attributable to Chemours of $274 million was 27.9 percent better than the prior-year quarter's $380 million net loss, and the Q2 2026 Adjusted Net Income of $64 million was 29.7 percent below the prior-year quarter's $91 million. The combination of the 128 percent year-over-year Free Cash Flow improvement, the 46 percent Free Cash Flow conversion, the 4.4x net leverage declining toward the 3x long-term target, the additional global TiO2 price increase effective June 1, 2026, and the 8 percent year-over-year APM Performance Solutions Net Sales growth serving data center and semiconductor end markets is the cleanest single-sentence read on what the specialty chemistry business model is producing, and the combination is the source of the operating-leverage spread the equity offers the buy-side.
The numbers tell the story with the kind of operational detail the specialty chemistry equity has been waiting for. The Q2 2026 Adjusted EBITDA of $247 million was 5.0 percent below the prior-year quarter's $260 million, with the decline reflecting a strong prior-year comparison from TSS aftermarket performance. The Q2 2026 Adjusted EPS of $0.42 was 31.1 percent below the prior-year quarter's $0.61, with the decline reflecting the Adjusted EBITDA dynamics. The Q2 2026 GAAP loss per diluted share of $1.81 was 28.5 percent better than the prior-year quarter's $2.53 GAAP loss per diluted share.
The Q2 2026 net sales dynamics included a 4 percent volume decline, a 2 percent price increase, and a 1 percent currency tailwind, with the pricing actions reflecting the discipline of the Pathway to Thrive strategy. The APM Performance Solutions Net Sales grew 8 percent year over year, with the growth underscoring the momentum and mix shift toward high-value specialty products serving the data center and semiconductor end markets.
The Q2 2026 Free Cash Flows improved 128 percent year over year, with the Free Cash Flow Conversion at 46 percent and the net leverage declining to 4.4x, advancing Chemours toward the long-term target of sustaining leverage below 3x. The deleveraging execution is the cleanest single read on the balance sheet management the company is producing.
The Q2 2026 capital structure actions include the improved cash generation and the reduced gross debt, with the company advancing resolution of notable legacy litigation. The Pathway to Thrive strategy is the cleanest single read on the management framework the company is positioning itself around.
The question the next four quarters resolve is whether the company can sustain the Free Cash Flow improvement and the deleveraging execution, and whether the TiO2 pricing actions and the APM Performance Solutions growth can continue through the second half of fiscal 2026. A Q3 2026 print that continues the Free Cash Flow improvement and the TiO2 pricing actions would confirm the operating profile is sustainable. A Q3 2026 print that shows Free Cash Flow deteriorating or the TiO2 pricing actions reversing would force the market to reprice the equity for a more modest terminal value.